Alzheimers Disease

July 12, 2018

Alzheimer’s Disease (AD) is the most common form of dementia and accounts for 60% to 80% of dementia cases. In this progressive disease, dementia symptoms gradually worsen over a number of years. Memory loss is mild during the early stages, but individuals with late-stage Alzheimer's lose the ability to carry on a conversation and respond to their environment. The greatest known risk factor is increasing age, and the majority of people with Alzheimer's are 65 and older. That said, up to 5% of people with the disease have early onset Alzheimer's, which often appears when someone is in their 40s or 50s1. Studies indicate that people aged 65 and older survive an average of four to eight years after diagnosis of Alzheimer’s disease, yet some live as long as 20 years or more, demonstrating the slow, insidious progression of the disease.

Spotlight

Fagron

From local player to global market leader and consolidator in the market of pharmaceutical compounding.

OTHER WHITEPAPERS
news image

Infosys and Top Pharma Bring Digital Transformation to DrugManufacturing Data

whitePaper | April 1, 2022

In 2017, a top 20 global pharmaceutical company began a journey to digitally transform its pharmaceutical engineering and manufacturing capabilities by constructing a data integration and visualization platform, with strategic assistance and technical implementation provided by its partner Infosys.

Read More
news image

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Read More
news image

Starting Materials For Homeopathic Drug Products

whitePaper | December 31, 2021

The scope of this white paper includes GMPs relevant for mass manufacturing/batch53 processing of products intended for widescale retail marketing. Starting materials and 54 packaging components for drug products

Read More
news image

Addressing Viral Pandemics Such as COVID-19 Using the Carterra® LSA

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

Read More
news image

Empowering MSLs to be the kings of Pharma’s New Frontier

whitePaper | December 12, 2022

To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy

Read More
news image

Adapting to Pharma’s Next Normal

whitePaper | October 4, 2022

Let’s just say what we’re all thinking: 2020 was rough. It threw every element of our lives into disarray. We suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive and it was challenging, but it was also transformative

Read More

Spotlight

Fagron

From local player to global market leader and consolidator in the market of pharmaceutical compounding.

Events